I think it's unclear currently. There are two [Technical difficulty—Editor]
The first is that the multilateral initiative, Covax, to further fair and equitable distribution of the vaccine, is underfunded. It is particularly underfunded in the resources it needs to build up the infrastructure, and it has been underfunded for distribution in countries. It is also underfunded with regard to the resources it needs to purchase advance doses. That's the first sign of concern.
The second is that many nations, my own and Canada included, have entered into large [Technical difficulty—Editor] purchase agreements for vaccines, which are inherently rivalrous with the multilateral initiative. They compete with it in the sense that they use up resources that otherwise might go to the multilateral initiative. They also reserve scarce vaccine manufacturing capacity.
There is a possibility that nations that have secured a significant amount of doses will be able to share them once they've addressed their own needs. It is unclear in terms of the time frame in which that will happen, and that may also depend on which vaccines succeed. The mRNA vaccines that are the most likely to be approved require a cold chain that we have not funded in nations to establish, so those are not going to address global needs. The question is, will other vaccines also generate the information they need to achieve regulatory approval? We don't know the answer to that yet.